Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
-
A-1155463 br Introduction Heart failure HF is a chronically
2024-10-15
Introduction Heart failure (HF) is a chronically progressive disease and one of the most important causes of morbidity and mortality worldwide despite recent improvements in its treatment [1], [2], [3]. The mortality and morbidity benefits of angiotensin converting enzyme inhibitor (ACEI) are wel
-
br Introduction Breast cancer is the second
2024-10-15
Introduction Breast cancer is the second most lethal cancer among women, accounting for approximately 40,000 deaths in the United States in 2015 [1]. The prognosis of breast cancer has improved significantly with the identification of immunohistochemical subtypes that predict response to therapy
-
The excellent safety profile of solanezumab and encouraging
2024-10-15
The excellent safety profile of solanezumab and encouraging trends in the exploratory analyses in mild AD led to its inclusion in two secondary prevention trials, which are continuing in the hope that earlier intervention may yield more substantial benefit. The A4 study (NCT02008357) started in Febr
-
br Funding This study was supported
2024-10-15
Funding This study was supported by a grant from the Science and Technology Program of Guangzhou (No. 2014Y2-00181) and the personnel training program of Southern Medical University (No. PY2015N023). Conflict of interest statement Authors’contributions Introduction Chronic cerebral hypo
-
naloxone hydrochloride receptor When a clinician diagnoses a
2024-10-15
When a clinician diagnoses a person with AD, the person is transformed into a patient with the disease. The person is a member of a patient group associated with behaviors, abilities, and experiences related both formally and informally to the diagnosis [10]. The diagnostic label implies what signs
-
The effect of capital deductions
2024-10-15
The effect of capital deductions on equilibrium prices is given by the following comparative statics Thus, equilibrium prices are strictly decreasing in the share of capital cost deduction. The reason is that a higher share of capital cost deduction reduces the effective marginal costs, which makes
-
The obtained results indicate that even when the impairment
2024-10-15
The obtained results indicate that even when the impairment of the same forms of memory are present, amnesia can develop in different ways. Impairment of memory reconsolidation in the conditioned food aversion model through both the serotonin receptor antagonist and the antagonist of NMDA glutamate
-
br Introduction In the past two decades
2024-10-14
Introduction In the past two decades, graphene and graphene based nanomaterials with unique physicochemical properties have attracted great attentions in many fields including biomedicine and biotechnology. Graphene oxide (GO) and its derivatives have shown promising potential as biological and c
-
Furthermore we also found that the basic level of ROS
2024-10-14
Furthermore, we also found that the basic level of ROS was markedly lower in mtDNA-reduced SW480 acetylcholine chloride receptor than that in the parent cells. Endogenous ROS is most notably produced at the sites of complex I and complex III [5], it might be plausible that the decreased quantity of
-
To better illustrate the involved
2024-10-14
To better illustrate the involved neuronal postganglionic pathways, central apelin-13 injection was performed in rats received peripheral preadministration of NOS inhibitor L-NAME, sympatholytic agent guanethidine and/or muscarinic receptor agonist bethanechol. Compared with the rats received vehicl
-
We report here the first
2024-10-14
We report here the first study on the inhibitory effects of the organic nitrates – on human erythrocyte GR. The previous reports by Becker et al., investigated other nitro derivatives (including arylizoalloxazines) by using Beutler’s method, monitoring GR inhibition. Data of show inhibition of hGR b
-
beta lactamase inhibitor Overall we found maternal antibioti
2024-10-14
Overall, we found maternal beta lactamase inhibitor to be associated with improved outcomes. In these multiple logistic regression models, high postnatal empiric infant antibiotic exposure was not significantly associated with risk for NEC or LOS. However, consistent with previous studies,5, 6 rece
-
Recent retrospective cohort studies have
2024-10-14
Recent retrospective cohort studies have supported these preclinical findings in animals indicating the correlation of AR activation with the induction of pilocarpine hydrochloride receptor carcinogenesis. First, men with prostate cancer who underwent androgen deprivation therapy were shown to have
-
The control group participants of the current study were ver
2024-10-14
The control group participants of the current study were very similar in age to those of Puertas et al. There was no significant correlation between age and enzyme activity over the short age span studied although age-related changes in the activity of ApA and aspartyl aminopeptidase, typically incr
-
br Applications of ATN in clinical
2024-10-14
Applications of ATN in clinical trials In pivotal trials, the use of biomarkers will also have to be considered in the context of regulatory risk and scrutiny. Although an important intended application of the framework is in research studies, its use will undoubtedly impact clinical development